Execution delays in battery and semiconductor verticals
Pilot plant capex delayed due to equipment arrival; second phase of battery chemicals capex spills into FY27. Any further delays could impact revenue ramp-up.
medium · management_commentaryAcutaas Chemicals Limited — Q3 FY26
Acutaas Chemicals delivered a stellar Q3 FY26 with revenue of ₹393.2 cr (+43% YoY), EBITDA of ₹150.7 cr (margin 38.3%, +1335 bps YoY), and PAT of ₹106.2 cr (+133.7% YoY).
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Product concentration risk in CDMO
Top CDMO product (oncology) drives a significant portion of growth. Analyst raised concern about concentration; management acknowledged but did not provide specific derisking timeline.
medium · analyst_questionChinese competition in intermediates
Chinese competitors remain a threat across segments. Management claims strong chemistry capabilities and market leadership in key products, but competition could pressure pricing.
medium · analyst_questionWorking capital days elevated
Net working capital days at 111, with debtor days at 100. Management considers 110 days standard, but any deterioration could strain cash flows.
low · data_observation